• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance- Suzhou,

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2026 Mar 15:108552.
doi: 10.1016/j.ijid.2026.108552. Online ahead of print.
Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance- Suzhou, Eastern China

Pengwei Cui[SUP] 1 [/SUP], Suizan Zhou[SUP] 2 [/SUP], Anna N Chard[SUP] 2 [/SUP], Junrong Wang[SUP] 1 [/SUP], Kathrine R Tan[SUP] 2 [/SUP], Ying Song[SUP] 2 [/SUP], Yuanyuan Pang[SUP] 1 [/SUP], Yuanyuan Zhang[SUP] 1 [/SUP], Huiyan Yu[SUP] 3 [/SUP], Zefeng Dong[SUP] 1 [/SUP], Zhiyuan Zhu[SUP] 4 [/SUP], Yayun Tan[SUP] 1 [/SUP], Haibing Yang[SUP] 1 [/SUP], Haitao Wang[SUP] 1 [/SUP], Xiaokun Yang[SUP] 5 [/SUP], Zhibin Peng[SUP] 5 [/SUP], Kathryn E Lafond[SUP] 2 [/SUP], Eduardo Azziz-Baumgartner[SUP] 2 [/SUP], Liling Chen[SUP] 6 [/SUP]


Affiliations
Abstract

During this 2025/26 Northern Hemisphere influenza season, the predominant influenza A(H3N2) subclade K virus has binding site mutations and postvaccine sera reduced inhibition, raising concerns about antigenic differences with available vaccines. During November 2025- January 2026, 8,455 patients with influenza-like illness (ILI) and 4,479 patients with severe acute respiratory illness (SARI) were identified through 25 sentinel surveillance hospitals in Suzhou City, Jiangsu Province, China. Among enrolled ILI and SARI patients, 4,032 (47.7%) and 697 (15.6%) were influenza positive by RT-PCR, respectively. Of all influenza positives, four were influenza B Victoria and three were influenza A(H1N1)pdm09; all remaining positives were influenza A(H3N2). Among gene sequenced viruses isolated from 44 randomly-selected positive samples during the study period, 95% were influenza A(H3N2) subclade K. Generalized linear regression models indicated Northern Hemisphere 2025/26 influenza vaccines, including A/Croatia/10136RV/2023 (H3N2)-like viruses, reduced risk for influenza-associated outpatient visits by approximately one-half during the November 2025-January 2026 subclade K dominant months. We did not observe statistical significance, although the point estimate suggested a possible one-fifth reduction in influenza-associated hospitalizations. Increasing seasonal influenza vaccine coverage could relieve stress on the medical system during respiratory disease season.

Keywords: influenza; northern hemisphere; subclade K; vaccine effectiveness.

 
Back
Top Bottom